Axiron
Axiron, an underarm testosterone liquid, may be associated with an increased risk of heart attack, strokes and blood clots (including deep vein thrombosis and pulmonary embolism). A number of testosterone lawsuits have been filed on behalf of men who allegedly suffered these serious complications due to Axiron.
Axiron Lawsuit Reviews
Bernstein Liebhard LLP, a nationwide law firm that provides representation to the victims of dangerous drug side effects, is offering free legal reviews to men who may have experienced serious cardiovascular events due to their use of Axiron and other low-T therapies. To learn more, please call (888) 994-5118.
Axiron: What’s the Problem?
Axiron is a testosterone underarm liquid marketed by Eli Lilly & Co. It is applied once daily, at the same time each morning. Like other low-T therapies, Axiron is intended to treat primary hypogonadism and hypogonadotropic hypogonadism in men. The safety and efficacy of Axiron in men with “age-related hypogonadism” have not been established.
A growing body of evidence indicates that Axiron and other testosterone treatments may be associated with an increased risk of heart attack, stroke and blood clots. In recent years, the drugs have been the subject of various safety warnings:
- January 2014: The FDA announced it was reviewing the safety of Axiron and other low-T therapies amid concerns that the drugs might increase the risk of heart attacks and strokes in certain men.
- June 2014: The FDA orders new blood clot warnings for AndroGel and other prescription testosterone treatments, including pulmonary embolism (PE) and deep vein thrombosis (DVT). Read More
- March 2015: The FDA completes its cardiovascular review of testosterone products, and orders low-T manufacturers to add new warnings to their drug labels regarding a possible association with heart attacks and strokes. Read More
Some studies have also found a link between low-T treatments and cardiovascular complications:
- November 2013: A scientific paper published in JAMA suggests that use of prescription testosterone treatments is associated with a 25.7% risk of cardiovascular side effects, compared to 19.9% for men who were not on the drugs.
- January 2014: A study published in PLoS One found that men over 65 were twice as likely to have a heart attack if they used low-T treatments, while men under 65 with pre-existing heart disease were three times as likely to have a heart attack if they used the drugs.
Axiron Litigation News
- April 2015: An Axiron lawsuit filed on behalf of an Oklahoma woman blames the medication for her husband’s fatal cardiac arrest. The complaint accuses Eli Lilly of failing to warn patients that Axiron could increase the risk for heart attacks, stroke and other cardiovascular problems. Read More
- June 2014: Federal testosterone lawsuits filed on behalf of men who allegedly suffered heart attacks, strokes and blood clots due to their use of Axiron and other low-T therapies are centralized in the U.S. District Court, Northern District of Illinois. Read More
- October 2014: A New Jersey man who suffered a heart attack a month after starting treatment with Axiron files suit against Eli Lilly. He claims his suffering could have been avoided if he had been adequately warned by doctors about Axiron’s association with serious and life-threatening heart problems. Read More
Are You Eligible to File an Axiron Lawsuit?
You may be eligible to file an Axiron lawsuit if you suffered a heart attack, stroke or dangerous blood clot while using this low-T treatment. To learn more about the growing testosterone litigation, please call (888) 994-5118.
- FDA (2014) “FDA Drug Safety Communication: FDA evaluating risk of stroke, heart attack and death with FDA-approved testosterone products” http://www.fda.gov/Drugs/DrugSafety/ucm383904.htm
- FDA (2014) “FDA adding general warning to testosterone products about potential for venous blood clots” http://www.fda.gov/Drugs/DrugSafety/ucm401746.htm
- FDA (2015) “FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use” http://www.fda.gov/Drugs/DrugSafety/ucm436259.htm
- JAMA (2013) “Association of Testosterone Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone Levels” http://jama.jamanetwork.com/article.aspx?articleid=1764051
- PLoS One (2014) “Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men” http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0085805
Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.
Follow Us
